No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
www.staidson.comNo one on the platform currently holds 300204.SZ.
No tracked institution reports a position in 300204.SZ as of their last filing.
No one on the platform has traded 300204.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -32.2% | -12.3% | ||||
| Profit Margin % | -35.3% | -49.8% | -22.2% | |||
| Free Cash Flow Margin % | -91.9% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $471M | +40.2% | $0.03 | $0.03–$0.03 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300204.SZStaidson (Beijing) BioPharmaceuticals Co., Ltd. | $19.46 | +0.00% | $8.8B | — |
| 300009.SZAnhui Anke Biotechnology (Group) Co., Ltd. | $8.01 | +0.63% | $13.4B | — |
| 300049.SZInner Mongolia Furui Medical Science Co., Ltd. | $48.00 | +0.17% | $12.7B | — |
| 300253.SZWinning Health Technology Group Co., Ltd. | $6.67 | +0.91% | $14.7B | — |
| 300363.SZPorton Pharma Solutions Ltd. | $22.11 | +4.19% | $12.0B | — |
| 300436.SZFujian Cosunter Pharmaceutical Co., Ltd. | $85.27 | +0.46% | $13.6B | — |
| 300601.SZShenzhen Kangtai Biological Products Co., Ltd. | $11.73 | +0.60% | $13.1B | — |
Source: Financial Modeling Prep · peers by sector/industry